David R. Liu - 19 Oct 2022 Form 3 Insider Report for Prime Medicine, Inc. (PRME)

Role
10%+ Owner
Signature
/s/ Carman Alenson attorney-in-fact
Issuer symbol
PRME
Transactions as of
19 Oct 2022
Transactions value $
$0
Form type
3
Filing time
19 Oct 2022, 20:06:43 UTC
Next filing
26 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PRME Common Stock 20,835,277 19 Oct 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRME Stock Option (right to buy) 19 Oct 2022 Common Stock 93,515 $3.67 Direct F1
holding PRME Series A Convertible Preferred Stock 19 Oct 2022 Common Stock 321,665 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 5, 2021, subject to the Reporting Person's continued consulting service on each such vesting date.
F2 The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") are convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney